Syntex Cardene (nicardipine)
Executive Summary
The calcium channel blocker received U.K. market approval on July 16 for the treatment of angina and hypertension. Syntex submitted an angina NDA in the U.S. for nicardipine last year. Syntex said it expects to complete its submission for hypertension in this calendar year. Syntex currently markets the drug for hypertension and angina in Denmark and for cerebrovascular insufficiency in Spain.